...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Announces Corporate Update Conference Call & Webcast on June 18, 2020 and US$5 Million Equity Investment

,,yes disappointing to have a down draft in the offering share price, especially when we are so much more advanced than on previous occasions. Makes one scratch their head as to why the Zenith sales teams' pitch is not making greater headway in advancing the speculation of future worth of this company and its molecules,,,!!,,tuff times for our management team in garnering respectful valuations in these companies..the deal seems more one sided for Newsorara,,,,,it looks on the outside that we will make a deal with almost anyone with almost any terms,,,same as RVX!!...jmo

Share
New Message
Please login to post a reply